Publications by authors named "Chohee Yun"

Claim this Profile
E
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Chohee Yun

Intest Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
Silvio Danese, Marc Ferrante, Brian G Feagan, Laurent Peyrin-Biroulet, Toshifumi Hibi, Chohee Yun

Am J Gastroenterol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects.
Chia-Hsiang Hsueh, Kacey Anderson, Gong Shen, Chohee Yun, Ann Qin

Clin Transl Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Brian G Feagan, Silvio Danese, Edward V Loftus, Séverine Vermeire, Stefan Schreiber, Chohee Yun

Lancet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
Kacey Anderson, Yan Xin, Hao Zheng, Chohee Yun, Ellen Kwan

Clin Pharmacol Drug Dev· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases.
Samuel J S Rubin, Lawrence Bai, Yeneneh Haileselassie, Gotzone Garay, Chohee Yun

Nat Commun· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Chun-Jen Liu, Wan-Long Chuang, I-Shyan Sheen, Horng-Yuan Wang, Chi-Yi Chen, Chohee Yun

Gastroenterology· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Jordan J Feld, Alnoor Ramji, Stephen D Shafran, Bernard Willems, Paul Marotta, Chohee Yun

Clin Infect Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
Stefan Zeuzem, Masashi Mizokami, Stephen Pianko, Alessandra Mangia, Kwang-Hyub Han, Chohee Yun

J Hepatol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
Jürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, Chohee Yun, Hadas Dvory-Sobol

Lancet Gastroenterol Hepatol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
Massimo Colombo, Alessio Aghemo, Hong Liu, Jie Zhang, Hadas Dvory-Sobol, Chohee Yun

Ann Intern Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Jason Grebely, Stefan Mauss, Ashley Brown, Jean-Pierre Bronowicki, Massimo Puoti, Chohee Yun

Clin Infect Dis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.
Hyerang Roh, Hankil Son, Donghwan Lee, HeeChul Chang, Chohee Yun, Kyungsoo Park

Clin Ther· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Massive gastrointestinal dilatation in a case of hereditary hollow visceral myopathy.
Robert J Huang, Chohee Yun, Linda Nguyen

Dig Liver Dis· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
Hankil Son, Hyerang Roh, Donghwan Lee, Heechul Chang, Junku Kim, Chohee Yun, Kyungsoo Park

Clin Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRAF6 mediates IL-1β/LPS-induced suppression of TGF-β signaling through its interaction with the type III TGF-β receptor.
Seunghwan Lim, Eunjin Bae, Hae-Suk Kim, Tae-Aug Kim, Kyunghee Byun, Byungchul Kim, Chohee Yun

PLoS One· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TrkC plays an essential role in breast tumor growth and metastasis.
Wook Jin, Gyoung Mi Kim, Min Soo Kim, Mi Hee Lim, Chohee Yun

Carcinogenesis· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-beta signaling in neuronal stem cells.
Chohee Yun, Jonathan Mendelson, Tiffany Blake, Lopa Mishra, Bibhuti Mishra

Dis Markers· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway.
Wook Jin, Chohee Yun, Joon Jeong, Yangho Park, Hy-De Lee

J Biol Chem· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling.
Wook Jin, Chohee Yun, Hae-Suk Kim, Seong-Jin Kim

Cancer Res· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Wook Jin, Chohee Yun, Amy Hobbie, Matthew J Martin, Poul H B Sorensen

Cancer Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis